2018
DOI: 10.1590/0004-282x20180041
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The therapeutic effect of IVIG for prevention of postnatal relapses in MS could not clearly be established in this meta-analysis.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
10
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 15 publications
(10 citation statements)
references
References 19 publications
0
10
0
Order By: Relevance
“…Methylprednisolone can be used during breastfeeding since transfer to breastmilk is low, as noted above [68,69]. Intravenous immune globulin (IVIG) is not a standard treatment for MS relapses, and while controversial, recent data have not supported its use in prophylaxis against postpartum relapses [71]. Furthermore, risks of venous thromboembolism associated with IVIG are of particular concern in the postpartum period when this risk is already elevated.…”
Section: Pharmacologic Treatment Postpartummentioning
confidence: 99%
“…Methylprednisolone can be used during breastfeeding since transfer to breastmilk is low, as noted above [68,69]. Intravenous immune globulin (IVIG) is not a standard treatment for MS relapses, and while controversial, recent data have not supported its use in prophylaxis against postpartum relapses [71]. Furthermore, risks of venous thromboembolism associated with IVIG are of particular concern in the postpartum period when this risk is already elevated.…”
Section: Pharmacologic Treatment Postpartummentioning
confidence: 99%
“…The use of intravenous immunoglobulin (IVIG) has generated conflicting results in published papers. Although IVIG has a good safety profile, a recent meta-analysis demonstrated an ineffective cost–benefit profile from prescribing IVIG for prevention of relapses during the puerperium [ 34 ]. Different therapeutic schemes have been used; there are some uncontrolled studies and some studies controlled with 30-year-old historical patient data [ 34 ].…”
Section: Management Of Relapses After Deliverymentioning
confidence: 99%
“…Although IVIG has a good safety profile, a recent meta-analysis demonstrated an ineffective cost–benefit profile from prescribing IVIG for prevention of relapses during the puerperium [ 34 ]. Different therapeutic schemes have been used; there are some uncontrolled studies and some studies controlled with 30-year-old historical patient data [ 34 ]. Briefly, using the present information on IVIG, approximately six women must be treated to avoid one relapse, which translates into a cost of over US$80,000 to prevent of a single postnatal MS relapse.…”
Section: Management Of Relapses After Deliverymentioning
confidence: 99%
“…In a retrospective analysis of study of patients who were followed in a database, 20 subjects who were given monthly intravenous methylpredisolone (1 g) for six months post-partum had a lower annualized relapse rate for the first three months post-partum than those who had no treatment [125]. There have been suggestions that intravenous immunoglobulin (IVIG) could be useful in preventing post-partum relapses [126,127,128] but a meta-analysis has failed to confirm this [129].…”
Section: Post-partum Relapsesmentioning
confidence: 99%